ANGO
ANGIODYNAMICS INC
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$11.39
+1.33%Oct 14, 2026, 11:00 UTC
HUMANA INC updated its Medicare Advantage coverage policy to apply Local Coverage Determination L40205 medical-necessity criteria to irreversible electroporation for prostate and liver cancer.
Source:Oct 8, 2026, 17:44 UTC
ANGIODYNAMICS INC shares fell more than 21% on Thursday.
Source:Oct 8, 2026, 12:22 UTC
ANGIODYNAMICS INC reported a quarterly loss of $0.04 per share, compared with a loss of $0.10 per share a year earlier.
Source:Oct 8, 2026, 10:02 UTC
AngioDynamics reported first-quarter fiscal 2027 net sales of $80.9 million for the quarter ended August 31, 2026.
Source:Oct 8, 2026, 10:00 UTC
ANGIODYNAMICS INC announced Eric Honroth’s appointment as president and chief executive officer and a member of its board, effective November 2, 2026, succeeding Jim Clemmer.
Source:Oct 2, 2026, 10:00 UTC
AngioDynamics and The PERT Consortium named Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York as recipients of an ALPHA-PE Research Fund award to support an independent investigator-led study on pulmonary embolism.
Source:Sep 28, 2026, 20:30 UTC
AngioDynamics announced it will report its fiscal 2027 first quarter financial results before market open on October 8, 2026, with a management conference call at 8:00 am ET the same day.
Source:Jul 14, 2026, 12:21 UTC
AngioDynamics reported its fiscal fourth quarter 2026 financial results, posting a net loss of $0.07 per share, which beat the Zacks Consensus Estimate of a loss of $0.11 per share.
Jun 18, 2026, 14:55 UTC
AngioDynamics received FDA IDE approval for its NanoKnife BPH feasibility study.
Source:Jun 17, 2026, 12:30 UTC
AngioDynamics received FDA IDE approval for the RELIEF feasibility study evaluating its NanoKnife IRE platform for treating benign prostatic hyperplasia.
Source: